Longevity & AgingNew Monthly GLP-1 Drug Shows 7% Weight Loss in Early Human Trial
MBX Biosciences has released early Phase 1 data for MBX 4291, a new weight-loss drug designed to be taken just once a month. In a small group of participants, the drug produced an average of 7% body weight loss over eight weeks, with some individuals losing up to 16%. Notably, no nausea or vomiting was reported, which is a common complaint with existing GLP-1 drugs like semaglutide. The drug works by activating both GLP-1 and GIP receptors — the same dual mechanism behind tirzepatide — but is formulated as a prodrug that releases slowly, potentially enabling monthly rather than weekly injections. Larger cohort results are expected by late 2026.
